Taken together, these data demonstrate that EYA2 acts as a tumor suppressor to prevent the initiation and progression of HCC, while EYA2(A510E) mutant type attenuates the inhibitory function. The gene discussed is EYA2; the disease is hepatocellular carcinoma.